Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and 11...
Clinical Trial
Opthea Strengthens Team with Key Clinical and Regulatory Hires
Dr. Julie Clark, SVP Clinical Development; Dr. Fang Li, SVP Regulatory Affairs, to join February 1stExperienced executives bring extensive track...
Genflow Biosciences Releases 2023 Year-End Review and Highlights Key Priorities for 2024
Genflow Biosciences Plc ("Genflow" or "the Company") LONDON, Feb. 01, 2024 (GLOBE NEWSWIRE) -- The Company (LSE:GENF) (OTCQB:GENFF), an emerging...
Boomerang Medical Awarded “Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” by the Crohn’s & Colitis Foundation
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer in the...
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize...
Stemtech Corporation Expands Global Reach with New License Agreement in Africa
Stemtech Corporation Secures Exclusive Agreement to Propel Stemtech's Revolutionary Stem Cell Nutrition Across Six African NationsNAPLES, FL / ACCESSWIRE /...
Open Letter to Zomedica Shareholders from your Chief Executive Officer
ANN ARBOR, MI / ACCESSWIRE / January 31, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
MIAMI, FL, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life...
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the...
USGI Medical Receives FDA Approval to Conduct Pivotal Study of the POSE2.0® Incisionless Weight Loss Procedure for Primary Obesity
– Approval of IDE advances Company’s progress to make endoscopic gastroplasty an essential element of the primary obesity treatment algorithm...
Defence Therapeutics Completes 1st Tranche of Financing
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the...
Etiometry Unveils 2024 Priorities and Celebrates Milestones: Clinical Outcomes Data Show Significant Reductions in Length of Stay (LOS)
Building on a Transformative Year, Etiometry's Clinical Decision-Support Platform Attracts New Partnerships, Unprecedented Clinical Outcomes and Deeper Integration with the...
Etiometry Unveils 2024 Priorities and Celebrates Milestones: Clinical Outcomes Data Show Significant Reductions in Length of Stay (LOS)
Building on a Transformative Year, Etiometry's Clinical Decision-Support Platform Attracts New Partnerships, Unprecedented Clinical Outcomes and Deeper Integration with the...
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
Magdalena aiming to submit Investigational New Drug application in 2024 to the FDA for this next-generation psychoactive prescription drug candidate...
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML...
COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures
Funds will be used to support the advancement of COUR’s Myasthenia Gravis (MG) and Type 1 Diabetes (T1D) product candidates...
High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team up to advance the development of novel cancer therapies
Press Release High-Performance Computing, simulations and AI: Qubit Pharmaceuticals, Institut Curie and the University of Bordeaux team...
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy
Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing...
BioSenic patent granted in Canada for broader protection of ATO therapeutic platform
PRESS RELEASE – INSIDE INFORMATION BioSenic patent granted in Canada for broader protection of its ATO therapeutic platform Composition-of-matter...